Pneumococcal dosing regimen

Patent metadata

Field	Value
Publication number	US-9669084-B2
Application number	US-201414322167-A
Country	US
Kind code	B2
Filing date	Jul 2, 2014
Priority date	May 8, 2006
Publication date	Jun 6, 2017
Grant date	Jun 6, 2017

Abstract

Methods of immunizing older adult subjects against Streptococcus pneumoniae infection are provided. Provided methods comprise immunization of naïve adult subjects with a conjugated pneumococcal polysaccharide vaccine. Optionally, initial immunization may be followed by additional immunization doses comprising conjugated pneumococcal polysaccharide vaccine or unconjugated pneumococcal polysaccharide vaccine composition.

First claim

What is claimed is:

1. A method of eliciting an immunoprotective antibody response to a capsular polysaccharide of Streptococcus pneumoniae in an older subject comprising administering to an older subject an immunogenic amount of an initial pneumococcal polysaccharide conjugate vaccine, wherein the subject has previously received a pneumococcal unconjugated polysaccharide vaccine, wherein the prior administration of the pneumococcal unconjugated polysaccharide vaccine was administered at an interval selected from the group consisting of at least one year, at least two years, and at least five years prior to administration of the initial pneumococcal polysaccharide conjugate vaccine, wherein the initial pneumococcal polysaccharide conjugated vaccine is selected from the group consisting of a 7-valent, 9-valent, 10-valent, 11-valent and 13-valent conjugated vaccine, wherein the conjugated vaccine comprises polysaccharides of serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F, each of which is conjugated to a non-toxic CRM 197 variant of diphtheria toxin, and wherein the pneumococcal unconjugated polysaccharide vaccine comprises polysaccharides of serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F.

2. The method of claim 1 , further comprising administering at least one additional vaccine dose.

3. The method of claim 2 , wherein the additional dose of vaccine is selected from the group consisting of a pneumococcal polysaccharide conjugate vaccine composition, an unconjugated pneumococcal polysaccharide vaccine composition, and combinations thereof.

4. The method of claim 2 , wherein the additional dose of vaccine is administered at a time selected from the group consisting of about two weeks, about one month, about six weeks, about two months, about three months, about six months, about nine months, about twelve months, about fifteen months, about eighteen months, about twenty-one months and about twenty-four months following the initial conjugate vaccine administration.

5. The method of claim 2 , wherein at least two additional vaccine doses are administered following the initial conjugate dose and wherein the at least two additional doses are administered at intervals comprising at least about one year after the prior dose.

6. The method of claim 5 , wherein the at least two additional vaccine doses are administered in an administration interval selected from the group consisting of one year, five years, and ten years after the prior dose.

7. The method of claim 6 , wherein the at least two additional vaccine doses comprise a pneumococcal polysaccharide conjugate vaccine.

8. The method of claim 6 , wherein the at least two additional vaccine doses comprise an unconjugated pneumococcal polysaccharide vaccine.

9. The method of claim 1 , wherein the conjugate vaccine further comprises polysaccharides of serotypes 1 and 5, each of which is conjugated to a non-toxic CRM 197 variant of diphtheria toxin.

10. The method of claim 1 , wherein the conjugated vaccine further comprises polysaccharides of serotypes 1, 5, and 7F, each of which is conjugated to a non-toxic CRM 197 variant of diphtheria toxin.

11. The method of claim 1 , wherein the conjugated vaccine further comprises polysaccharides of serotypes 1, 3, 5, and 7F, each of which is conjugated to a non-toxic CRM 197 variant of diphtheria toxin.

12. The method of claim 1 , wherein the conjugated vaccine further comprises polysaccharides of serotypes 1, 3, 5, 6A, 7F, and 9A, each of which is conjugated to a non-toxic CRM 197 variant of diphtheria toxin.

13. The method of claim 7 , wherein the pneumococcal polysaccharide conjugate vaccine comprises polysaccharides of serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F, each of which is conjugated to a non-toxic CRM 197 variant of diphtheria toxin.

14. The method of claim 7 , wherein the pneumococcal polysaccharide conjugate vaccine comprises polysaccharides of serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F, each of which is conjugated to a non-toxic CRM 197 variant of diphtheria toxin.

15. The method of claim 7 , wherein the pneumococcal polysaccharide conjugate vaccine comprises polysaccharides of serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F, each of which is conjugated to a non-toxic CRM 197 variant of diphtheria toxin.

16. The method of claim 7 , wherein the pneumococcal polysaccharide conjugate vaccine comprises polysaccharides of serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9A, 9V, 14, 18C, 19F, and 23F, each of which is conjugated to a non-toxic CRM 197 variant of diphtheria toxin.

Assignees

• Wyeth Llc

Inventors

• Siber George Rainer
• Paradiso Peter R
• Hackell Jill
• Lockhart Stephen Paul
• Hausdorff William P

Classifications

• A61K39/385

  Haptens or antigens, bound to carriers · CPC title

• A61K39/092 Primary

  Streptococcus · CPC title

• A61K2039/6037

  Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT] · CPC title

• A61K39/02

  Bacterial antigens · CPC title